# US 2012/0232058 A1 · Substituted pyridine derivatives and their medical use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232058 A1
- Document ID: US20120232058A1
- Status: Published application
- Kind: A1
- Application number: 13/394,468
- Filed: 2010-09-02
- Published: 2012-09-13
- Earliest claimed: 2009-09-07
- Assignees: NeuroSearch A/S
- Inventors: William Dalby Brown; Carsten Jessen; Dorte Strøbæk
- Web page: https://patentgrep.com/patent/US20120232058A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61P 9/12: Antihypertensives
- A61P 13/10: of the bladder
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to novel substituted pyridine derivatives, to their use in therapy, to pharmaceutical compositions comprising the derivatives, to the use of said derivatives in the manufacture of a medicament, and to therapeutic methods comprising the administration of the derivatives. The present derivatives are useful for treating a disorder responsive to activation of Kv7 channels. Formula (I).

## Claims

### Claim 1

A compound of Formula (I)
a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein
R1 represents C1-6-alkyl;
R3 represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one or more times with substituents selected from C1-6-alkyl, C1 -6-alkoxy, halo and trifluoromethyl;
R4 represents C1-6-alkyl; and
R5 and R6, together with the nitrogen to which they are attached, form a heterocyclic ring selected from morpholinyl and 1,4-oxazepanyl.

### Claim 2 (depends on 1)

The compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R1 represents metyl or iso-propyl.

### Claim 3 (depends on 1)

The compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R3 represents furanyl which is optionally substituted with C1-6-alkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R4 represents C1-6-alkyl.

### Claim 5 (depends on 1)

The compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R5 and R6, together with the nitrogen to which they are attached, represents 1,4-oxazepanyl.

### Claim 6 (depends on 1)

The compound according to claim 1, which is:
3-Methyl-furan-2-carboxylic acid(2-isopropyl-4-methyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide; or
3-Methyl-furan-2-carboxylic acid(2,4-dimethyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide;
or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

### Claim at position 8

-15. (canceled)

### Claim 16 (depends on 1)

A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to activation of Kv7 channels, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of the compound according to claim 1, a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the disease, disorder or condition is pain, bipolar disorders, mania, psychosis, depression, anxiety and schizophrenia.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the disease, disorder or condition is a compulsive behaviour, epilepsy, Lennox-Gastaut, convulsions, seizures, seizure disorders, absence seizures, general seizures, partial seizures, vascular spasms or hypertension.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the disease, disorder or condition is pain, mild, moderate or severe pain, acute, chronic or recurrent pain, neuropathic pain, pain caused by migraine, migraine, migraine-related disorders, postoperative pain, phantom limb pain, neuropathic pain, chronic headache, tension type headache, central pain, pain related to diabetic neuropathy, to post therapeutic neuralgia, or to peripheral nerve injury.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the disease, disorder or condition is bladder control, nocturia, bladder spasms, overactive bladder (OAB), bladder outflow obstruction, interstitial cystitis (IC) or urinary incontinence.
